Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tildrakizumab Signals Safe for Pregnant Psoriasis Patients

Publish date:: February 7, 2020

Key clinical point: No identifiable safety concerns were found among women who were pregnant while participating in tildrakizumab clinical trials.

Major finding: Pregnancy outcomes among 14 women taking tildrakizumab included 6 fetal losses, 4 elective abortions, and 8 live births, with no congenital anomalies.

Study details: The data come from a post hoc analysis of nine clinical trials including 528 female patients and 14 reported pregnancies.

Disclosures: The studies were supported by Merck Sharp & Dohme, a Merck & Co. subsidiary; analyses were supported by Sun Pharmaceutical Industries. Lead author Dr. Haycraft and other authors disclosed relationships with Sun Pharmaceutical Industries, as well as Celgene, Lilly, Novartis, Ortho-Derm, and Pfizer.

Citation:

FROM THE BRITISH JOURNAL OF DERMATOLOGY

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Dermatology

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

More severe AD correlates with worse sleep health and attention problems in children,

Shortcomings identified in study of acne videos on TikTok,

Study results support screening rosacea patients for cardiometabolic disease,

No lab monitoring needed in adolescents on dupilumab,